Clinical Trial Update: Efficacy and Safety of Inclisiran as Monotherapy in Patients With Primary Hypercholesterolemia Not Receiving Lipid-lowering Therapy. [Phase 3]

View source ↗

Summary

Phase 3 results assess the efficacy and safety of Inclisiran as monotherapy in patients with primary hypercholesterolemia not receiving lipid-lowering therapy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypercholesterolemia

Drugs mentioned

• Inclisiran (inclisiran)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Hypercholesterolemia | Phase 3 | Status: COMPLETED | Results posted: 2025-08-13